Coherus Oncology Appoints Arvind Sood As Chief Strategy And Corporate Affairs Officer To Strengthen Strategic And External Relations

Coherus Oncology, Inc. has announced the appointment of Arvind Sood as Chief Strategy and Corporate Affairs Officer. He will report directly to Denny Lanfear, Chairman and Chief Executive Officer of the company. In his new role, Mr. Sood will oversee key strategic and external relations functions, supporting Coherus Oncology’s mission to advance innovative cancer therapeutics and strengthen its corporate and investor communications.

Welcoming Mr. Sood to the company, Denny Lanfear said, “We are thrilled to have such a highly respected biotechnology leader join Coherus Oncology as we continue to develop next-generation cancer therapies and expand LOQTORZI® revenues in nasopharyngeal carcinoma. Our CCR8-targeting antibody, CHS-114, is progressing rapidly in head and neck, gastric, esophageal, and colorectal cancers, while our IL-27 antagonist, casdozokitug, is advancing in liver and lung cancer. Arvind’s extensive experience and strategic insight will help us strengthen our engagement with the global investment community and potential corporate partners, further highlighting the value and promise of our oncology pipeline.”

Arvind Sood expressed his enthusiasm about joining the company, stating, “I am excited to be part of Coherus Oncology at a pivotal stage in its transformation into a fully focused oncology company. The breadth and strength of its pipeline across multiple cancer types present significant opportunities for innovation and growth. I look forward to contributing to the company’s efforts to deliver therapies that can meaningfully improve patient outcomes while creating value for shareholders. It is particularly notable that Coherus retains global rights to CHS-114 and casdozokitug, offering potential business development opportunities for partnerships outside the U.S., which we plan to actively pursue.”

Mr. Sood brings over two decades of experience from leading global biotechnology and pharmaceutical organizations. He spent more than 20 years at Amgen, where he served as Vice President of Investor Relations, before taking on leadership roles as President of U.S. Operations at Innate Pharma and Chief Operating Officer at Curogen, a South Korean biotechnology company. 

Earlier in his career, he held positions at Aventis SA (now Sanofi) in investor relations, financial communications, and strategy, as well as various commercial roles in sales and marketing at The Upjohn Company (now Pfizer). Mr. Sood holds a Master of Business Administration (MBA) from Central Michigan University and a Bachelor of Business Administration (BBA) from Western Michigan University.